Ipsen with­draws NDA for rare bone dis­ease treat­ment less than 3 months af­ter win­ning pri­or­i­ty re­view

Af­ter win­ning pri­or­i­ty re­view for its ul­tra-rare bone dis­ease pro­gram at the end of May, Ipsen made an abrupt about-face Fri­day.

Ipsen with­drew its NDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.